MiniMed Group, Inc. (MMED)
| Market Cap | 6.13B |
| Revenue (ttm) | 3.22B +15.7% |
| Net Income | -314.00M |
| EPS | -1.19 |
| Shares Out | 281.35M |
| PE Ratio | n/a |
| Forward PE | 32.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,287,367 |
| Open | 21.50 |
| Previous Close | 22.50 |
| Day's Range | 21.27 - 22.73 |
| 52-Week Range | 10.65 - 24.43 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 24.83 (+13.95%) |
| Earnings Date | Sep 1, 2026 |
About MMED
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company’s platform includes Automated Insulin Delivery (AID) systems for... [Read more]
Financial Performance
In fiscal year 2026, MiniMed Group's revenue was $3.10 billion, an increase of 14.25% compared to the previous year's $2.72 billion. Losses were -$333.00 million, 56.3% more than in 2025.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for MMED stock is "Buy." The 12-month stock price target is $24.83, which is an increase of 13.95% from the latest price.
News
MiniMed files S-4 in connection with Medtronic exchange offer
MiniMed (MMED) announced that it has filed a Form S-4 Registration Statement with the SEC in connection with Medtronic’s (MDT) offer to exchange up to 225,361,295 shares of MiniMed common…
Medtronic launches exchange offer to complete separation of MiniMed
Medtronic (MDT) announced that it has commenced an exchange offer to split off at least 80.1% of the shares of MiniMed Group (MMED). MiniMed, formerly Medtronic’s Diabetes business, completed its…
Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.
Medtronic shareholders can exchange their Medtronic ordinary shares for shares of MiniMed Provides Medtronic shareholders with option for a generally tax-free exchange for U.S. federal income tax pu...
MiniMed Files Form S-4 Registration Statement in Connection with Medtronic Exchange Offer Announcement
NORTHRIDGE, Calif., Sept. 14, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) announced that it has filed a Form S-4 Registration Statement today with the Securities and Exchange Commission (the "SEC") in...
MiniMed Group Transcript: Wells Fargo 21st Annual Healthcare Conference
U.S. growth accelerated in Q1 due to new product launches, with Fit patch pump and Vivera algorithm set to expand the market, especially among Type 2 patients. Manufacturing and pharmacy strategies are in place to support upcoming launches, while international growth remains robust. Guidance and profitability targets are reaffirmed.
MiniMed Group Quarterly report: Q2 2026
MiniMed Group has published its Q2 2026 quarterly earnings report on September 8, 2026.
MiniMed price target raised to $21 from $19 at Morgan Stanley
Morgan Stanley raised the firm’s price target on MiniMed (MMED) to $21 from $19 and keeps an Overweight rating on the shares. The firm made “modest” adjustments to its model…
MiniMed price target raised to $25 from $20 at Deutsche Bank
Deutsche Bank raised the firm’s price target on MiniMed (MMED) to $25 from $20 and keeps a Buy rating on the shares.
MiniMed price target raised to $27 from $20 at Evercore ISI
Evercore ISI analyst Daniel Markowitz raised the firm’s price target on MiniMed (MMED) to $27 from $20 and keeps an Outperform rating on the shares.
MiniMed price target raised to $26 from $21 at Mizuho
Mizuho raised the firm’s price target on MiniMed (MMED) to $26 from $21 and keeps an Outperform rating on the shares following the fiscal Q1 report. With momentum from Flex…
MiniMed price target raised to $28 from $25 at UBS
UBS raised the firm’s price target on MiniMed (MMED) to $28 from $25 and keeps a Buy rating on the shares.
MiniMed price target raised to $28 from $25 at BTIG
BTIG raised the firm’s price target on MiniMed (MMED) to $28 from $25 and keeps a Buy rating on the shares. The firm is positive on the company’s better-than-expected Q1…
MiniMed price target raised to $28 from $24 at BofA
BofA raised the firm’s price target on MiniMed (MMED) to $28 from $24 and keeps a Buy rating on the shares. MiniMed delivered a “solid” fiscal Q1 beat, but pipeline…
MiniMed price target raised to $26 from $23 at Citi
Citi raised the firm’s price target on MiniMed (MMED) to $26 from $23 and keeps a Buy rating on the shares. The company reported better than expected fiscal Q1 results,…
MiniMed price target raised to $26 from $22 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised the firm’s price target on MiniMed (MMED) to $26 from $22 and keeps an Overweight rating on the shares. The company reported a Q1…
MiniMed jumps after upping fiscal 2027 organic growth outlook
Shares of MiniMed (MMED) are moving higher following the company’s fiscal Q1 earnings report. For fiscal 2027, MiniMed expects organic revenue growth of 10.5%, a raise from the prior guidance…
MiniMed Group Earnings Call Transcript: Q1 2027
Q1 delivered 16% organic revenue growth, driven by strong U.S. and international performance, new product launches, and expanding recurring revenue streams. Fiscal 2027 guidance was raised, with margin expansion expected as separation costs decline and new products ramp globally.
MiniMed Group Earnings release: Q1 2027
MiniMed Group released its Q1 2027 earnings on September 1, 2026, summarizing the period's financial results.
MiniMed Group Slides: Q1 2027
MiniMed Group has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on September 1, 2026.
MiniMed Group Slides: Investor presentation
MiniMed Group has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
MiniMed reports Q1 EPS 0c, consensus 9c
Reports Q1 revenue $843M, consensus $828.43M. “MiniMed (MMED) delivered an excellent start to our fiscal year, with accelerating U.S. growth, continued double-digit international growth, and strong ex...
MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
Strong start to fiscal year with net sales of $843 million growing 17% as reported and 16% organic U.S. net sales growth accelerated to 13%; continued robust international net sales growth of 18% as r...
MiniMed to Participate in Upcoming Investor Conferences
NORTHRIDGE, Calif., Aug. 25, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that management will participate in fireside chats at the following in...